- Home
- VVPR vs BTAI Comparison
VVPR vs BTAI Comparison
Compare VVPR & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VVPR | BTAI |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.2M | 43.7M |
| IPO Year | 2016 | 2018 |
Fundamental Metrics
Financial Performance| Metric | VVPR | BTAI |
|---|---|---|
| Price | $2.28 | $1.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $26.67 |
| AVG Volume (30 Days) | 437.6K | ★ 658.1K |
| Earning Date | 09-02-2023 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $61,000.00 | ★ $752,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $265.60 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 281.25 | N/A |
| 52 Week Low | $0.62 | $1.17 |
| 52 Week High | $8.88 | $8.08 |
Technical Indicators
Market Signals| Indicator | VVPR | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 41.95 | 47.68 |
| Support Level | $2.12 | $1.76 |
| Resistance Level | $2.50 | $2.08 |
| Average True Range (ATR) | 0.24 | 0.14 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 19.31 | 33.33 |
Price Performance
Historical ComparisonAbout VVPR VivoPower International PLC
Vivopower International PLC is a sustainable energy solutions B Corporation specializing in electric solutions for customized and ruggedized fleet applications, battery and microgrids, solar, and critical power technology and services. The company's core purpose is to provide turnkey decarbonization solutions that help customers progress toward net-zero carbon status. VivoPower operates across five reportable segments: Electric Vehicles, Sustainable Energy Solutions, Solar Development, Digital Assets, and Corporate Office, with personnel and operations in Australia, the Netherlands, the United Kingdom, the United States, and the Philippines.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.